You are here

Article Text

Article menu
Download PDFPDF
Commentary
Maternal and child health
Associations between the timing and dosing of aspirin prophylaxis and term and preterm pre-eclampsia
  1. Lisa Askie1,
  2. Lelia Duley2
  1. 1 NHMRC Clinical Trials Centre, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
  2. 2 Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK
  1. Correspondence to Professor Lisa Askie, NHMRC Clinical Trials Centre, Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia; lisa.askie{at}ctc.usyd.edu.au

https://doi.org/10.1136/bmjebm-2018-110931

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of pretermand term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 2018;218:287–93.

    Context

    Aspirin prophylaxis during pregnancy has been estimated in a participant-level meta-analysis to reduce the risk of pre-eclampsia by 10%.1 Evidence-based guidelines recommend aspirin for high-risk women, usually 75 mg from 12 weeks’ gestation and if possible before 20 weeks.2 Despite decades of research, controversy remains regarding the optimal dose and timing of aspirin treatment to prevent pre-eclampsia.

    While a meta-analysis using individual participant data (IPD) concluded that the effect on pre-eclampsia is consistent regardless of whether treatment starts before or after 16 weeks,3 an aggregate data meta-analysis concluded that a lower dose of aspirin (<100 mg) started after 16 weeks has ‘modest or no impact’.4 Another recent IPD meta-analysis suggested a dose–response effect …

    View Full Text

    Footnotes

    • Contributors LA and LD drafted and approved the finalised manuscript.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.